Related Experiment Videos
Total and local changes in the arthritis adjuvans
J Martínek1, H Hulejová, M Adam
1Department of Histology and Embryology, 1st Medical Faculty, Charles University, Prague, Czech Republic. jmart@lf1.cuni.cz
General Physiology and Biophysics
|March 9, 2000
Summary
Methotrexate demonstrated significant benefits in treating adjuvant arthritis in mice. It stabilized monocyte levels, reduced synovial inflammation, and decreased tumor necrosis factor-alpha (TNF-alpha) in this arthritis model.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Adjuvant arthritis is a murine model used to study inflammatory joint diseases.
- Understanding the efficacy of different treatments is crucial for managing arthritis.
Purpose of the Study:
- To evaluate the effects of methotrexate, tauredon, and collagen hydrolysate on adjuvant arthritis in mice.
- To assess the impact of these treatments on disease progression and key inflammatory markers.
Main Methods:
- Mice with adjuvant arthritis were treated with methotrexate, tauredon, or collagen hydrolysate.
- Evaluations included body weight, leukograms, paw and tail edema measurements.
- Histopathological and immunohistochemical analyses were performed to assess interleukin-1-beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha).
Main Results:
- Methotrexate showed the most significant beneficial effects.
- Methotrexate stabilized blood monocyte levels.
- It reduced synovial membrane cell invasion and TNF-alpha immunopositivity.
Conclusions:
- Methotrexate is a promising therapeutic agent for adjuvant arthritis.
- Its efficacy is linked to modulation of inflammatory cell populations and cytokine expression.